< Back to previous page
Researcher
Zeger Debyser
- Disciplines:Laboratory medicine, Microbiology, Systems biology, Biomaterials engineering, Biological system engineering, Biomechanical engineering, Other (bio)medical engineering, Environmental engineering and biotechnology, Industrial biotechnology, Other biotechnology, bio-engineering and biosystem engineering
Affiliations
- Molecular Virology and Gene Therapy (Division)
Responsible
From1 Jan 2012 → Today - Molecular Virology and Gene Therapy (Division)
Member
From1 Jan 2013 → Today - Faculty of Medicine, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2003 → 29 Feb 2008 - Faculty of Medicine (Faculty)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
1 - 10 of 75
- DEVELOPMENT OF LINE-1 INHIBITORSFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Design of targeted degraders of LEDGF/p75 with applications as anticancer agentsFrom25 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- HIV Latency and the epigenetic landscape: studying individual patients for developing HIV cure strategiesFrom1 Mar 2023 → TodayFunding: Geopolitical funding in general (R&D collaboration with Central and Eastern Europe
- Towards a functional cure strategy of HIV infection: Single virus imaging to study the impact of HIV nuclear import and integration on transcription and latencyFrom1 Sep 2022 → TodayFunding: FWO fellowships
- INNOVATIVE THERAPIES FOR LINE-1 DISEASEFrom1 May 2022 → TodayFunding: BOF - various
- Single virus live imaging of HIV nuclear import and integrationFrom1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
- Targeting LEDGF/p75 for Mixed Lineage Leukemia and chemoresistant malignanciesFrom16 Oct 2021 → TodayFunding: FWO fellowships
- Role of the epigenetic reader LEDGF/p75 in health and diseaseFrom1 Oct 2021 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- Role of the interaction between LEDGF and MeCP2 in LINE-1 retrotransposition in the brainFrom1 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Epigenetic regulation of HIV transcription: Towards a block-and- lock functional cureFrom16 Jul 2021 → TodayFunding: FWO fellowships
Publications
1 - 10 of 289
- Development of novel therapeutic strategies for rare CFTR mutations causing severe cystic fibrosis(2023)
Authors: Marjolein Ensinck, Zeger Debyser, Christiane De Boeck, Marianne Carlon
- Determinants of Retroviral Integration and Implications for Gene Therapeutic MLV-Based Vectors and for a Cure for HIV-1 Infection(2023)
Authors: Eline Pellaers, Anayat Bhat, Frauke Christ, Zeger Debyser
- Expansion microscopy allows high resolution single cell analysis of epigenetic readers(2022)
Authors: Boris Louis, Susana Neves Rocha, Thierry Voet, Zeger Debyser, Johan Hofkens
- Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site(2022)
Authors: Zeger Debyser
- Studying an array of biological questions at the nanoscale with Expansion Microscopy: From cells to viruses(2022)
Authors: Aline Acke, Johan Hofkens, Susana Neves Rocha, Zeger Debyser
- LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators(2022)
Authors: Siska Van Belle, Tine Brouns, Marianne Carlon, Frauke Christ, Zeger Debyser
Pages: 133 - 140 - A ubiquitous disordered protein interaction module orchestrates transcription elongation(2021)
Authors: Jonas Demeulemeester, Zeger Debyser
Pages: 1113 - + - CRISPR/Cas9-Induced Mutagenesis Corroborates the Role of Transportin-SR2 in HIV-1 Nuclear Import(2021)
Authors: Julie Janssens, Rik Gijsbers, Frauke Christ, Zeger Debyser
- GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture(2021)
Authors: Anne Bruggemans, Frauke Christ, Zeger Debyser
- Role of Transportin-SR2 in HIV-1 Nuclear Import(2021)
Authors: Julie Janssens, Frauke Christ, Zeger Debyser
Patents
1 - 9 of 9
- Functional cure of retroviral infection (Inventor)
- Functional cure of retroviral infection (Inventor)
- Thieno[2,3-b]pyridine derivatives as viral replication inhibitors (Inventor)
- Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors (Inventor)
- Functional cure of retroviral infection (Inventor)
- ;Antiviral compounds (Inventor)
- THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS (Inventor)
- NOVEL ANTIVIRAL COMPOUNDS (Inventor)
- VIRAL REPLICATION INHIBITORS (Inventor)